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SATB2-associated syndrome (SAS) is a recently-identified disorder characterized by 
neurodevelopmental deficits and craniofacial anomalies. Assessments of speech, language, and 
feeding-related issues were conducted among 61 individuals with SAS (median age=86 months, 
range=26 months to 29 years of age). Individuals with SAS were mostly non-verbal 
communicators (72.1%) with severe deficits in both language comprehension and expression. 
The majority of individuals had receptive vocabulary skills of a child younger than 3-years of 
age. Based on parent report the average spoken lexicon was 28.6 (sd=84.6) (n=55) with a range 
of 0 to 500 (median=5 words). All of the individuals with SAS with enough verbal ability either 
showed signs of childhood apraxia of speech or already had a diagnosis (n=40) and 73.3% 
exhibited problems with reliable communication with unfamiliar partners. Hypernasal resonance 
(17.8%) due to velopharyngeal insufficiency secondary to a history of cleft palate and/or apraxic 
palatal movement (60.0% of hypernasal patients with no history of cleft palate), problems with 
chewing (68.2%), overstuffing the mouth with solids (64.9%), pharyngeal phase dysphagia 
(60.8%), and sialorrhea (63.3%) were common in this population. Mutation type was not 
predictive of receptive or expressive language abilities. We developed language and 
communication treatment recommendations based on these findings.   





SATB2- associated syndrome (SAS) is a multisystem disorder caused by alterations of the 
SATB2 gene manifesting as craniofacial anomalies and neurodevelopmental problems warranting 
multidisciplinary assessment and management.1-3 The reported craniofacial phenotype in SAS 
includes facial dysmorphic features, palatal abnormalities (cleft palate, high-arched palate, 
submucous cleft palate, bifid uvula), micrognathia, and several dental anomalies.1,2,4 
Neurodevelopmental problems among individuals with SAS are characterized by intellectual 
disability, global developmental delay, limited or absent verbal speech, behavioral issues 
(autistic-like features, jovial/overly-social personality), epilepsy, and feeding difficulties.4  
Verbal communication is the area of development most severely impacted in SAS 3,4. 
Previous reports indicate that affected individuals often demonstrate significant impairment of 
verbal communication abilities, receptive and language deficits, reliance on augmentative and 
alternative communication (AAC) modalities, features potentially consistent with apraxia of 
speech, and hallmarks of an autism spectrum disorder.1,2,4-13 
While the development of receptive language abilities beyond those of expressive 
language have been reported in several individuals, the degree of verbal impairment is reported 
to be variable, ranging from absent or near absent to more developed, yet still substantially 
delayed.3,4 Furthermore, other comorbid palatal anomalies and feeding difficulties that can have 
an impact of speech production, have been reported to commonly occur in SAS.1,2,4-15 
We here present the first report of speech, language, and feeding difficulties conducted 
using direct assessments and screening procedures in a large cohort of individuals with SAS 
from different demographic and genetic backgrounds. Data for progression of skills is presented 
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and genotype-phenotype correlations on speech outcomes explored. Based on our results, we 
provide additional language and feeding recommendations for care of individuals with SAS. This 
information can be used to inform treating clinicians and families of individuals with SAS about 
expectations and best practices.  
Subjects and Methods 
Subjects 
As part of two separate multidisciplinary international clinics which took place in 2017 
and 2018, individuals with SAS were evaluated by the following specialties: genetics, speech, 
audiology, otolaryngology, dentistry, orthodontics, maxillofacial surgery, and psychiatry. All 
individuals were confirmed to have the diagnosis of SAS and their medical records were reviewed, 
including prior cognitive evaluations, when available. Based on a literature review of the known 
speech-language and feeding characteristics of individuals with SAS, speech-language 
pathologists (SLPs) evaluated the domains of receptive language, expressive language, speech 
production, resonance, and feeding using subtests from standardized speech tests, criterion-
referenced speech screening tools, rubric-based subjective scales, clinician observations, and 
parent interview. Evaluations were conducted in English. As subtests and criterion-referenced 
items were standardized on English-speakers, data from individuals whose primary language was 
not English could not be used for those assessments. 
Molecular studies 
 Except for a single individual (SATB2-85), remaining participants were included in 
previous publications detailing their clinical and genetic investigations.3,4,8,9Individual SATB2-
85 underwent molecular cytogenetic studies with an array CGH+SNP (4x180, Agilent 
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Technologies, Santa Clara, CA). Underlying molecular alterations were grouped for analysis as 
follows: large chromosomal deletions or duplications (2q33.1 deletions and duplications 
encompassing SATB2 and other contiguous genes), truncating pathogenic variants (predicted 
nonsense and frameshift), intragenic deletions, canonical splice site, and missense variants. All 
families reported herein agreed to share clinical information and were enrolled under a research 
clinical registry protocol approved by the Institutional Review Board of the University of 
Arkansas for Medical Sciences. 
Receptive language and communication skills  
Each individual’s receptive language abilities were assessed using the Vocabulary subtest 
of the Test for Auditory Comprehension of Language-Fourth Edition (TACL-4) 16 
(Supplementary materials and methods). The TACL-4 scaled subtest was interpreted as average 
(8-13), low average (7), mild deficit (6), moderate deficit (5), or severe deficit (1-4). Overall 
communication abilities were rated using the Communication Function Classification System 
(CFCS).17 The CFCS provides 5 levels (CFCS I, II, III, IV, V) to describe everyday 
communication performance with sending and receiving messages via any modality (e.g. spoken 
language, sign language, speech-generating electronic devices, etc.) with familiar and unfamiliar 
communication partners. Individuals with SAS were rated on the CFCS scale based on clinical 
judgment of overall language abilities using any communication modality.  
Speech Intelligibility Individuals who had the verbal ability to imitate words were 
administered the LinguiSystems Articulation Test (LAT) - Apraxia Screening Summary.18 The 
LAT Apraxia Screening Summary is based on the child’s sequential productions of twelve 
multisyllabic words across three trials. Inconsistent repetition of a multisyllabic word, a hallmark 
sign of Childhood Apraxia of Speech (CAS), has been previously assessed as a screening tool in 
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other genetic conditions.19-21 Evaluating clinicians phonetically transcribed utterances clinically 
judged to be in known context (e.g. a child pointed to his sister named Jenna and produced an 
utterance with similar phonetic similarity such as “Zin-uh”) and compared those phonetically 
transcribed words to the target word. Clinicians analyzed the error patterns in the transcribed 
utterances. The analysis of these error patterns included consideration for characteristics of a 
phonological delay, an articulation deficit, and CAS. Signs of CAS, including vowel errors, 
idiosyncratic errors, and prosody differences were a basis to form a clinical impression of CAS 
characteristics.   
Resonance 
Among individuals determined to be verbal communicators, with the verbal speaking 
abilities to imitate words, clinicians evaluated each patient’s resonance. The following perceptual 
11 point scale was used by the evaluating SLPs to rate resonance: -5, severely hyponasal; -4, 
moderately-severely hyponasal; -3, moderately hyponasal; -2, mildly-moderately hyponasal; -1, 
mildly hyponasal; 0, within normal limits; 1, mildly hypernasal; 2, mildly-moderately 
hypernasal; 3, moderately hypernasal; 4, moderately to severely- hyponasal; 5, severely 
hyponasal. Individuals with components of both hypernasality and hyponasality were listed as 
having mixed resonance with two separate numeric ratings for both hypernasality and 
hyponasality. SLPs noted the presence or absence of nasal air emission (NAE): visible NAE 
assessed through use of detail reflector mirror, audible NAE assessed perceptually by clinical 
assessment of speech productions, or both. Clinicians also noted clinical signs of velopharyngeal 
insufficiency. Medical records were reviewed to identify a history of cleft palate or submucous 
cleft palate.   
Feeding, language acquisition, expressive vocabulary, modes of communication 
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Evaluating SLPs developed a SAS-specific parent interview questionnaire to assess 
language acquisition, expressive vocabulary, and modes of communication (Supplementary 
materials and methods). When parents provided an estimated range, rather than a whole-number 
estimation, the median value was used for data analysis (e.g. parent estimation of “10 to 20 
words” was given a value of 15 words). Additionally, evaluating SLPs noted clinical impressions 
regarding the mean length of utterance used during the session. SLPs categorized individuals as 
either primarily verbal or non-verbal under the following criteria: 1) primarily non-verbal, 
reportedly uses no more than 10 words in a day and uses non-verbal communication more often 
than verbal, or 2) primarily verbal, reportedly uses more than 10 words in a day and uses 
speaking as primary mode of communication. External medical records were also reviewed to 
supplement information obtained from the clinic visit and parental report in all cases.  
Statistics 
Demographics and clinical characteristics of speech, language, and feeding were assessed 
as categorical (number, percent) or continuous measures (mean, standard deviation [sd]; median, 
interquartile range [IQR], range). Chi-square, Fisher’s exact, or t-tests were used, as appropriate, 
to quantify the impact of molecular alterations on speech outcomes (e.g. genotype-phenotype 
associations). 
Results 
Baseline demographic and clinic characteristic are summarized in table 1 while results of 
screening procedures are described in table 2. Sixty-one individuals (31 males, 50.8%) of 
different ages (median=86 months, range=26 months to 29 years of age), with a variety of 
molecular alterations (42.6% with truncating variants), from seven different countries (88.5% 
from the United States) were evaluated during two separate clinics (n=9, 14.8% were evaluated 
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twice). The most common primary mode of communication was gestures (59.0%), either alone 
or in combination with signs and/or AAC while verbal communication was primarily used by 14 
(22.9%) individuals. Cognitive evaluations had been completed for 11 individuals (range: 34-
78). Supplementary Table 1 features speech production, language, cognitive, and feeding data 
gathered for each individual in this cohort. Supplementary tables 2 and 3 detailed molecular 
results for each individual. 
Receptive and expressive language skills are significantly affected in individuals with SAS  
  The average raw score for the TACL-4 Vocabulary subtest was 10.1 (n=60, sd=10.7); a 
raw score below 15 has an age equivalent of less than 3-years 0-months for this subtest (Figure 
1). Scores ranged from 0 to 38 (the highest scoring individual being a 13-year old having an age 
equivalent of 5-years 9-months for this subtest), with 17 individuals (29%) scoring 0 by not 
correctly identifying any receptive vocabulary words (e.g. home, box, girl, drink). Scaled TACL-
4 Vocabulary subtest scores were also reflective of significant impairment (mean=2.0,sd=1.6) 
with 76.8% (43/56) below <1st centile rank (Figure 1). 
 Of the 61 individuals with SAS assessed, 72.1% (n=44) were primarily nonverbal. The 
average age of reported first words was 27.6 months (sd=14.4) with a range from 8-months to 
66-months (n=44, only includes individuals who have spoken first words). Based on parent 
report the average spoken lexicon of individuals with SAS (n=55) was 28.6 (sd=84.6) words, 
with a range of 0 to 500 (median=5 words) (Figure 1). However, this average includes three 
individuals with estimated spoken vocabularies of 200, 350, and 500 words. Excluding those 
three individuals with markedly higher expressive language abilities than other individuals with 
SAS, the average fell to 10 words (sd=16.2; median=4.3). The remaining 52 individuals had an 
average expressive lexicon of 2.5 words for children under 3-years of age, 6.2 words for children 
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3-years 1-month through 6-years 0-months, 13.9 words for children 6-years 1-month through 12-
years 0-months, and 10.2 words for those 12-years 1-month through 29-years of age. For 
reference, 20 words in a child’s spoken vocabulary is typically achieved by 18-months of age 
and 200 words by 24-months of age 20. By caregiver report, 16% of individuals tested had no 
spoken vocabulary words. Individuals with large deletions, truncating mutations, missense 
mutations, and intragenic deletions were all represented among individuals with no spoken 
vocabulary words (Table 2). The “highest functioning” children evaluated in this cohort were an 
8-year 0-month old boy (SATB2#53) with an estimated spoken vocabulary of 200 words who 
receives >120 minutes of speech therapy per week, a 5-year 6-month-old boy (SATB2#004) with 
an estimated spoken vocabulary of 350 words who receives 120 minutes of speech therapy per 
week, and a 13-year 4-month old girl (SATB2#51) with an estimated spoken vocabulary of 500 
words who receives 60-90 minutes of speech therapy per week.   
Mean length of utterance (MLU) among 7 individuals who were classified as primarily 
verbal communicators was 2.39 words, ranging from 1.00 to 6.75. However, that utterance 
length drops to 1.67 words per utterance when omitting a high-functioning individual with an 
outlier MLU of 6.75. For reference, a MLU of 1.75 is typically reached by 26-months of age 22.   
Most individuals with SAS have difficulties with everyday communication  
On the CFCS, 73.3% (n=44) individuals exhibited problems with reliable communication 
with unfamiliar partners (CFCS III, IV, or V). Of the 60 individuals rated, 10 individuals 
(16.6%) were rated Level V (Seldom Effective Sender and Receiver even with familiar partners).  
Apraxia of speech is common in SAS 
Forty individuals with SAS had enough verbal ability for noting clinical characteristics of 
apraxia. Of these, 31 (77.5%) had received a prior diagnosis of CAS (22 also judged to have 
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characteristics of CAS during the clinic visit, 8 did not produce enough verbal utterances in 
known context for an adequate analysis, and 1 not screened). Nine additional individuals (22.5%) 
were judged to exhibit CAS based on hallmark characteristics noted by the SLP. The LAT-
Apraxia Screening Summary22 results revealed very low ability for consistently repeating 
multisyllabic words among 8 participants who were primarily verbal. The average number of 
words repeated consistently (not necessarily correctly) was 6.37 (ranging from 4 to 10), which 
was highly indicative of CAS.  
Oral-motor and resonance issues are prevalent in this population  
For individuals with SAS with enough verbal output for making a perceptual resonance 
judgment (n=28), 82.1% (n=23) had normal resonance, 7.1% (n=2) had perceptually mild 
hypernasal resonance, and 10.7% (n=3) had perceptually moderate hypernasal resonance during 
speech. There was no history of cleft palate in 60.0% (n=3) of individuals noted to have any 
hypernasal resonance. A history of cleft palate was noted with 36.1% (n=22) of individuals with 
SAS (n=61).   
A history of sialorrhea was reported in 63.3% (n=38 of 60 assessed) of individuals with SAS, 
with resolution reported by an average of 48 months (range of drooling cessation: 2.5 to 7-years 
of age). Among 24 individuals (40.0%), sialorrhea persisted beyond 48-months of age, though 
41.7% (n=10) reported significant improvements over time. Regarding feeding difficulties, 
64.9% (n=37 of 57 assessed) of individuals with SAS analyzed overstuffed their mouths during 
meals. Of the 22 individuals whose caregivers were asked about chewing, 68.2% (n=15) reported 
difficulty with chewing. While 60.8% (n=14 of 23 assessed) of individuals SAS had a reported 
history of pharyngeal dysphagia, 61.6% (n=37 of 60 assessed) of caregivers reported no present 
signs of aspiration.  
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Speech progression over time 
Nine individuals were seen in consecutive evaluations a year apart. All but two (77.8%) 
individuals made gains in his or her receptive vocabulary raw score with an average net gain of 
3.8 words (ranging from five fewer words to a gain of 19 words). Despite gains in raw scores, 
the net scaled score changed by -0.33 (ranging from a drop in 1 scaled score to no gain); 
reflecting slower acquisition of vocabulary compared to the rate of same-age peers. Likewise, 
spoken vocabulary grew in four of the nine (44.4%) returning individuals. The average net gain 
was 29.2 words (sd=82.9) among the 9 individuals. However, the average fell to 1.62 words 
(sd=5.7) when assessed without the one individual who gained over 250 words in the year 
between visits. From year-to-year, among those without gains, two had the same number of 
words, two more regressed from one spoken word to zero, and the last one regressed from 10 
words to 2-3 words. Two of those three (66.7%) individuals who regressed in spoken vocabulary 
had autism or were clinically suspected as having an autism spectrum disorder.  
 Genotype-phenotype correlations 
Overall, mutation type was not predictive of clinical features or language development (Table 2). 
Proportion of non-verbal individuals, mean TACL-4 raw and scaled scores, number of 
individuals with TACL-4 receptive age equivalent younger than 3 years of age, mean reported 
age at first words, mean CFCS level, and frequency of CAS diagnosis did not show statistical 
differences between molecular groups. Individuals with intragenic deletions did have a lower 





This study represents the first direct investigation of the impact of SAS on receptive language, 
expressive language, speech production, resonance, and feeding. Based on our findings and 
experience with this cohort of individuals, we present a summary of main findings along with 
recommendations for speech, language, resonance, and feeding below, also summarized in Table 
3.  
Individuals with SAS largely have significant deficits in receptive vocabulary skills 
relative to age. The majority of individuals had receptive vocabulary skills of a child younger 
than 3-years of age 16. As a cohort, individuals’ receptive vocabulary scaled scores were 
progressively less than those of same-age peers with less accelerated growth over time than 
neurotypical children. Despite these deficits, as the cohort aged, raw scores for receptive 
vocabulary skills improved over time for most. For those individuals that were seen on two 
occasions, we were able to document net improvement in receptive skills. Given the trend of 
receptive vocabulary growth across age and the improvement displayed by most returning 
participants after one year, SLPs treating individuals with SAS should continually target 
receptive vocabulary skills. As 29% of individuals with SAS exhibited scores of 0 in their TACL-
4 subtest scaled scores, managing SLPs may not be able to measure receptive language growth 
through pointing of pictures from an array presented. Non-verbal IQ testing should be considered 
for all individuals with SAS for educational planning to factor out the negative impact of a 
child’s language impairment when assessing their cognitive profile. 
Most individuals with SAS will not use spoken language as their primarily means of 
communication. With an average spoken lexicon of 28.6 words and average MLU for verbal 
participants of 1.67, individuals with SAS should be considered for AAC to enhance their 
expressive abilities. Presenting AAC earlier and at home and school, with appropriate training in 
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those settings, may improve expressive vocabulary growth. Mutation type was not predictive of 
speech outcomes. Several individuals with SAS are inconsistent senders and receivers of 
information with familiar partners and even greater number have problems communicating with 
unfamiliar partners.17 Targeted use of AAC to enable or augment communication should be 
implemented with a progressively growing circle of communication partners, and training of 
those communication partners as needed. 
 Essentially all children with enough verbal ability to screen informally with a criterion 
reference tool exhibited characteristics of CAS.19,20 Managing SLPs should assume that children 
with SAS will have motor planning deficits associated with apraxia as they develop verbal 
speech. Clinicians should target speech production with a motor-planning approach, not waiting 
until the child has enough verbal ability to corroborate an apraxia diagnosis with formal testing. 
A single randomized control trial of apraxia treatment approaches comparing the Nuffield 
Dyspraxia Programme-3 and the Rapid Syllable Transitions Treatment determined that when 
these interventions are delivered in intensive one-hour sessions four days per week across three 
weeks, patients demonstrate comparable gains in word accuracy one month after treatment with 
either therapy approach.23For individuals with CAS, higher dose or higher-dose frequency of 
intervention results in better outcomes than lower dose or dose frequency of those same 
interventions24 Individual therapy is recommended as it yields a higher frequency of responses.24 
It is of note that therapy intensity is comprised of many complex variables, including dose, dose 
form, dose frequency, session duration, and total intervention duration; therapy intensity and 
patient outcomes are not always positively correlated, and treatment intensity can reach a point 
of diminishing return.25 Intellectual disabilities and attention difficulties common in SAS, may 
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limit therapy dosage (number of responses per session) and sustained attention for long session 
durations. 
 Mild to moderate hypernasality was present in 18% of individuals and independent of a 
history of cleft palate. Resonance, particularly for hypernasality, should be monitored. The 
source of velopharyngeal insufficiency could be related to a history of cleft palate, mistiming of 
velopharyngeal closure secondary to motor planning deficits, or a co-occurrence of both. A 
referral to an otolaryngologist for nasendoscopy of assessment of velopharyngeal insufficiency 
should be made if clinicians perceive hypernasality and/or nasal air emission (not phoneme-
specific nasal air emission). Difficulty with chewing (68%) and overstuffing the mouth with 
solids (65%) were common among children with SAS; thus, feeding therapy may be warranted 
as part of the individual’s plan of care. We recommend monitoring for signs and symptoms of 
aspiration, as there is a high incidence of pharyngeal dysphagia (61%); a formal swallow study 
may be warranted to rule out aspiration and to determine if a patient needs compensatory 
strategies or thickened liquids to protect a child’s respiratory health. Lastly, while sialorrhea is 
common for individuals with SAS, it seems to improve over time.  
This study has several limitations and the results should be interpreted with some caution. 
While the sample size (61 individuals) is the largest cohort objectively analyzed for speech and 
language deficits, a larger prospective cohort is desirable to validate these results. Although all 
individuals have the diagnosis of SAS, different molecular alterations that resulted in this 
syndrome were included and some differences could be the result of other modifier genes and the 
impact of affected contiguous genes for those with large deletions and duplications was not 
analyzed. . Likewise, if the language phenotype seen in this population is commensurate with the 
individual’s general intellectual or functioning level could not be evaluated. Detailed cognitive 
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evaluations, while often attempted, could not yield a reliable IQ score to be reported in the 
majority of patients. Individuals from different countries of origin were included and language 
barriers could have contributed to reduced validity of results given via parent report. Speech and 
language outcomes could also have been impacted by hearing impairment in this cohort although 
no history of hearing loss was recorded for any of the individuals evaluated. The presence of 
articulation deficits and/or phonological delay and dysarthria of the velopharyngeal port could 
not be ruled out as a contributing or co-occurring factor to explain some of the results reported. 
Lastly, some of the information obtained for this study was based on parental recollection. To 
reduce error in the data, medical records were reviewed for all individuals. In summary, 
individuals with SAS have a plethora of language, speech production, resonance, and feeding 
deficits that go beyond the primarily reported speech delay. These difficulties can be pervasive 
and necessitate a comprehensive, ongoing, multidisciplinary approach. The language and 
communication treatment recommendations were developed based on the results of this study to 
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Figure legends  
Figure 1. A., B. TACL-4 raw and scaled scores by age; C., D. Reported lexicon median with 
interquartile range by age and molecular alteration.   
